{
    "clinical_study": {
        "@rank": "137852", 
        "brief_summary": {
            "textblock": "To generate real world evidence to compare clinical outcomes and patient health-related\n      quality of life, resulting from catheter ablation therapy with clinical outcome and patient\n      health-related quality of life resulting from drug therapy in China. An economic model will\n      be constructed, and using the clinical events evidence collected in this study, and China\n      long-term disease progression and local disease cost data to perform a cost-effectiveness\n      evaluation of Catheter Ablation versus Drug Therapy in AF (Paroxysmal plus Persistent AF)\n      patients."
        }, 
        "brief_title": "Health Economics Evaluation of Catheter Ablation Versus Drug Therapy in Atrial Fibrillation (AF) in China", 
        "completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "detailed_description": {
            "textblock": "The evidence generated by this study is expected to help inform medical decision makers with\n      the clinical and economic data of therapy for AF patients, and also provide policy decision\n      makers with information that can be considered /used to allocate funds for AF ablation and\n      permit patients to have access to appropriate treatment options for AF management."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with paroxysmal or persistent AF eligible for catheter ablation\n\n          -  Age 18 to 80 years\n\n          -  Able and willing to comply with all pre,post and follow-up testing and requirements.\n\n          -  Be able to sign IRB/EC approved informed consent form.\n\n        Exclusion Criteria:\n\n          -  Terminal illness with a life expectancy less than 1 year.\n\n          -  New York Heart Association (NYHA) Class III or IV\n\n          -  Previous recipient of catheter ablation therapy for AF\n\n          -  Bradycardia and previous recipient of pacemaker therapy\n\n          -  Previous recipient RFCA or ICD therapy\n\n          -  Uncontrolled hypertension\n\n          -  Recent cardiac events including MI, PCI, or valve or bypass surgery in the  preceding\n             3 months\n\n          -  Patients with serious hepatic and renal diseases\n\n          -  Pregnant or prepare to be pregnant in one year\n\n          -  For drug therapy arm, if the subject cannot be contacted via phone or the subject\n             shows his/her disagreement to this study at 30 day window, the subject will be\n             withdrawn from this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "A minimum of 150 subjects in the catheter ablation arm ,75 paroxysmal AF patients and 75\n        persistent AF patients, and 300 subjects in the drug treatment arm ,150 paroxysmal AF\n        patients and 150 persistent AF patients."
            }
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878981", 
            "org_study_id": "CAAF 2011"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Catheter Ablation versus Drug Therapy in AF in China", 
        "lastchanged_date": "June 13, 2013", 
        "number_of_groups": "1", 
        "official_title": "Health Economics Evaluation of Catheter Ablation Versus Drug Therapy in Atrial Fibrillation (AF) in China", 
        "overall_official": {
            "affiliation": "Beijing Anzhen Hospital", 
            "last_name": "Changsheng Ma, doctor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "the frequency of recurrence of Atrial Fibrillation/Flutter/Tachycardia", 
            "measure": "the frequency of recurrence", 
            "safety_issue": "No", 
            "time_frame": "9 months followup after baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878981"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Total mortality", 
                "measure": "Rate", 
                "safety_issue": "Yes", 
                "time_frame": "9 month follow up after baseline"
            }, 
            {
                "description": "Average total costs of ablation vs. drug therapy per patient", 
                "measure": "total cost", 
                "safety_issue": "No", 
                "time_frame": "9 months follow up"
            }, 
            {
                "description": "Stroke", 
                "measure": "Rate", 
                "safety_issue": "Yes", 
                "time_frame": "9 months follow up from baseline"
            }, 
            {
                "description": "Cardiovascular death/Arrhythmic death or Cardiac arrest/Heart failure death", 
                "measure": "Rate", 
                "safety_issue": "Yes", 
                "time_frame": "9 months from baseline"
            }, 
            {
                "description": "Cardiovascular or Cerebrovascular hospitalization", 
                "measure": "Duration", 
                "safety_issue": "No", 
                "time_frame": "9 months from baseline"
            }
        ], 
        "source": "Johnson & Johnson Medical, China", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johnson & Johnson Medical, China", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2013"
    }
}